Impact of monthly prescription cap on medication persistence among patients with hypertension, hyperlipidemia, or diabetes

Journal of Managed Care Pharmacy

Volumn 19, Issue 3, 2013, Pages 258-268

  Wang, Chi Chuan ^a   Wei, David ^b   Farley, Joel F ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA BLOCKER; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DIABETES MELLITUS; FEMALE; HEALTH CARE POLICY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MONTHLY PRESCRIPTION CAP; PRESCRIPTION; UNITED STATES;

EID: 84878899669     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.3.258     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of hypertension-United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep. 2011;60(4):103-08.
2. Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol- United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep. 2011;60(4):109-14.
3. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed March 4, 2013.
4. Lloyd-Jones D, Adams RJ, Brown TM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease & stroke statistics-2010 update: a report of the American Heart Association. Circulation. 2010;121(7):948-54.
5. Nichols GA, Arondekar B, Garrison LP Jr. Patient characteristics and medical care costs associated with hypertriglyceridemia. Am J Cardiol. 2011;107(2):225-29.
6. Priest JL, Cantrell CR, Fincham J, Cook CL, Burch SP. Quality of care associated with common chronic diseases in a 9-state Medicaid population utilizing claims data: an evaluation of medication and health care use and costs. Popul Health Manag. 2011;14(1):43-54.
7. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10(18):2973-85.
8. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437-43.
9. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-24.
10. Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord. 2006;6:48.
11. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-30.
12. Dragomir A, Cote R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48(5):418-25.
13. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598-605.
14. Perreault S, Dragomir A, White M, Lalonde L, Blais L, Berard A. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med. 2009;266(2):207-18.
15. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16(8):568-76.
16. Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009;65(10):1013-24.
17. Perreault S, Ellia L, Dragomir A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med. 2009;122(7):647-55.
18. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177-86.
19. Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care. 2010;16(8):589-600.
20. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
21. Stuart B, Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff (Millwood). 1999;18(2):201-12.
22. Farley JF. Medicaid prescription cost containment and schizophrenia: a retrospective examination. Med Care. 2010;48(5):440-47.
23. Fortess EE, Soumerai SB, McLaughlin TJ, Ross-Degnan D. Utilization of essential medications by vulnerable older people after a drug benefit cap: importance of mental disorders, chronic pain, and practice setting. J Am Geriatr Soc. 2001;49(6):793-97.
24. Soumerai S. Unintended outcomes of medicaid drug cost-containment policies on the chronically mentally ill. J Clin Psychiatry. 2003;64(Suppl 17): S19-S22.
25. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N Engl J Med. 1987;317(9):550-56.
26. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of limiting on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650-55.
27. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325(15):1072-77.
28. Martin BC, McMillan JA, Kotzan JA. Bias associated with missing outof- plan prescription data for medicaid recipients. J Res Pharmaceut Econ. 1996;7(3):65-77.
29. Hearne J. CRS report for Congress. Prescription drug coverage under Medicaid. February 6, 2008. Available at: http://aging.senate.gov/crs/medicaid16.pdf. Accessed March 4, 2013.
30. Bearden BA. Memorandum: Monthly prescription limits; clinical drug inquiry applications. State of Louisiana, Department of Health and Hospitals. February 27, 2003. Available at: http://www.lamedicaid.com/provweb1/Forms/RxLimits/scriptlimitsfeb1703.pdf. Accessed March 4, 2013.
31. U.S. Census Bureau. Metropolitan and micropolitan statistical areas main. Available at: http://www.census.gov/population/metro/. Accessed March 4, 2013.
32. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-39.
33. Schulz RM, Lingle EW, Chubon SJ, Coster-Schulz MA. Drug use behavior under the constraints of a Medicaid prescription cap. Clin Ther. 1995;17(2):330-40.